193 related articles for article (PubMed ID: 15479693)
1. Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARgamma independent mechanisms.
Galli A; Ceni E; Crabb DW; Mello T; Salzano R; Grappone C; Milani S; Surrenti E; Surrenti C; Casini A
Gut; 2004 Nov; 53(11):1688-97. PubMed ID: 15479693
[TBL] [Abstract][Full Text] [Related]
2. Antidiabetic thiazolidinediones induce ductal differentiation but not apoptosis in pancreatic cancer cells.
Ceni E; Mello T; Tarocchi M; Crabb DW; Caldini A; Invernizzi P; Surrenti C; Milani S; Galli A
World J Gastroenterol; 2005 Feb; 11(8):1122-30. PubMed ID: 15754392
[TBL] [Abstract][Full Text] [Related]
3. Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27KiP1 in human. Pancreatic carcinoma cells.
Motomura W; Okumura T; Takahashi N; Obara T; Kohgo Y
Cancer Res; 2000 Oct; 60(19):5558-64. PubMed ID: 11034103
[TBL] [Abstract][Full Text] [Related]
4. Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines.
Yang FG; Zhang ZW; Xin DQ; Shi CJ; Wu JP; Guo YL; Guan YF
Acta Pharmacol Sin; 2005 Jun; 26(6):753-61. PubMed ID: 15916743
[TBL] [Abstract][Full Text] [Related]
5. Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R.
Ferruzzi P; Ceni E; Tarocchi M; Grappone C; Milani S; Galli A; Fiorelli G; Serio M; Mannelli M
J Clin Endocrinol Metab; 2005 Mar; 90(3):1332-9. PubMed ID: 15585569
[TBL] [Abstract][Full Text] [Related]
6. Selective activation of PPARgamma inhibits pancreatic cancer invasion and decreases expression of tissue plasminogen activator.
Farrow B; O'Connor KL; Hashimoto K; Iwamura T; Evers BM
Surgery; 2003 Aug; 134(2):206-12. PubMed ID: 12947319
[TBL] [Abstract][Full Text] [Related]
7. Thiazolidinediones inhibit hepatocarcinogenesis in hepatitis B virus-transgenic mice by peroxisome proliferator-activated receptor gamma-independent regulation of nucleophosmin.
Galli A; Ceni E; Mello T; Polvani S; Tarocchi M; Buccoliero F; Lisi F; Cioni L; Ottanelli B; Foresta V; Mastrobuoni G; Moneti G; Pieraccini G; Surrenti C; Milani S
Hepatology; 2010 Aug; 52(2):493-505. PubMed ID: 20683949
[TBL] [Abstract][Full Text] [Related]
8. Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer.
Lin MS; Chen WC; Bai X; Wang YD
J Dig Dis; 2007 May; 8(2):82-8. PubMed ID: 17532820
[TBL] [Abstract][Full Text] [Related]
9. Rosiglitazone increases PPARgamma in renal tubular epithelial cells and protects against damage by hydrogen peroxide.
Sommer M; Wolf G
Am J Nephrol; 2007; 27(4):425-34. PubMed ID: 17622750
[TBL] [Abstract][Full Text] [Related]
10. Thiazolidinediones/PPARγ agonists and fatty acid synthase inhibitors as an experimental combination therapy for prostate cancer.
Mansour M; Schwartz D; Judd R; Akingbemi B; Braden T; Morrison E; Dennis J; Bartol F; Hazi A; Napier I; Abdel-Mageed AB
Int J Oncol; 2011 Feb; 38(2):537-46. PubMed ID: 21170507
[TBL] [Abstract][Full Text] [Related]
11. Activation of peroxisome proliferator-activated receptor gamma inhibits the growth of human pancreatic cancer.
Sasaki T; Fujimoto Y; Tsuchida A; Kawasaki Y; Kuwada Y; Chayama K
Pathobiology; 2001; 69(5):258-65. PubMed ID: 12107343
[TBL] [Abstract][Full Text] [Related]
12. Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones.
Weng JR; Chen CY; Pinzone JJ; Ringel MD; Chen CS
Endocr Relat Cancer; 2006 Jun; 13(2):401-13. PubMed ID: 16728570
[TBL] [Abstract][Full Text] [Related]
13. [Regulatory effects of peroxisome proliferator-activated receptor gamma on the growth of pancreatic carcinoma].
Dong YW; Wang XP; Wu K; Wu LY; Zhang RL
Zhonghua Nei Ke Za Zhi; 2003 Jul; 42(7):479-82. PubMed ID: 12921608
[TBL] [Abstract][Full Text] [Related]
14. Ligands for peroxisome proliferator-activated receptor gamma have potent antitumor effect against human renal cell carcinoma.
Yuan J; Takahashi A; Masumori N; Uchida K; Hisasue S; Kitamura H; Itoh N; Tsukamoto T
Urology; 2005 Mar; 65(3):594-9. PubMed ID: 15780399
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of cell invasion and morphological change by troglitazone in human pancreatic cancer cells.
Motomura W; Nagamine M; Tanno S; Sawamukai M; Takahashi N; Kohgo Y; Okumura T
J Gastroenterol; 2004; 39(5):461-8. PubMed ID: 15175945
[TBL] [Abstract][Full Text] [Related]
16. A peroxisome proliferator-activated receptor gamma antagonist induces vimentin cleavage and inhibits invasion in high-grade hepatocellular carcinoma.
Kim KR; Choi HN; Lee HJ; Baek HA; Park HS; Jang KY; Chung MJ; Moon WS
Oncol Rep; 2007 Oct; 18(4):825-32. PubMed ID: 17786342
[TBL] [Abstract][Full Text] [Related]
17. Peroxisome proliferator-activated receptor-γ inhibits pancreatic cancer cell invasion and metastasis via regulating MMP-2 expression through PTEN.
Li Y; Zhang DW; Lin DQ; Cao LQ
Mol Med Rep; 2015 Oct; 12(4):6255-60. PubMed ID: 26299428
[TBL] [Abstract][Full Text] [Related]
18. PPARγ-independent thiazolidinedione-mediated inhibition of NUR77 expression in vascular endothelial cells.
Hu Y; Liu HB; Simpson RW; Dear AE
J Endocrinol; 2011 Jan; 208(1):R1-7. PubMed ID: 20978184
[TBL] [Abstract][Full Text] [Related]
19. Troglitazone inhibits cell growth and induces apoptosis of B-cell acute lymphoblastic leukemia cells with t(14;18).
Takenokuchi M; Saigo K; Nakamachi Y; Kawano S; Hashimoto M; Fujioka T; Koizumi T; Tatsumi E; Kumagai S
Acta Haematol; 2006; 116(1):30-40. PubMed ID: 16809887
[TBL] [Abstract][Full Text] [Related]
20. Effects of rosiglitazone--peroxisome proliferators-activated receptor gamma (PPARgamma) agonist on cell viability of human pituitary adenomas in vitro.
Winczyk K; Kunert-Radek J; Gruszka A; Radek M; Ławnicka H; Pawlikowski M
Neuro Endocrinol Lett; 2009 Mar; 30(1):107-10. PubMed ID: 19300395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
